Biotech Veteran Dr. Lutz Hilbrich Joins HALIX as CEO to Lead Expansion in Biopharmaceutical Manufacturing

HALIX B.V., a leading contract development and manufacturing organization (CDMO), has appointed Dr. Lutz Hilbrich as its new Chief Executive Officer (CEO). With over two decades of experience in biotechnology and pharmaceuticals, Dr. Hilbrich steps into the role immediately, bringing a wealth of knowledge in strategic leadership, operational management, and biopharmaceutical innovation. He succeeds Alex Huybens, under whose leadership HALIX grew into a key player in the development and manufacturing of cutting-edge therapeutic antibodies and viral products.

Dr. Hilbrich has worked extensively across the globe, including in the US, China, Europe, and Africa, driving growth and transformation in both large pharmaceutical corporations and mid-sized biotech companies. His leadership in areas such as biosimilars, cell and gene therapy, and vaccine development positions him well to take HALIX to the next level of growth. "Healthcare is a fundamental right," he said. "As a physician and biotech executive, I am committed to shaping the future of medicine. HALIX has established itself as a trusted partner in biopharmaceutical development, and I am eager to build on this solid foundation."

A Track Record of Innovation and Growth

HALIX, headquartered in Leiden, Netherlands, has gained a reputation for its state-of-the-art facilities and dedication to innovation. The company specializes in the GMP manufacturing of viral vectors and recombinant proteins, essential for the production of complex biopharmaceuticals used in treating life-threatening diseases. Its recent expansion into recombinant proteins further strengthens its position as a leading CDMO in the industry.

Notably, HALIX played a crucial role in the global fight against COVID-19 by partnering with AstraZeneca for the large-scale production of its COVID-19 vaccine. This collaboration showcased HALIX’s ability to operate on a global scale, contributing to pandemic response efforts and supporting healthcare initiatives around the world.

Leadership Transition

Dr. Harry Flore, Chairman of the Supervisory Board, expressed his enthusiasm for the new appointment: "We are thrilled to welcome Dr. Hilbrich as our new CEO. His deep experience in biosimilars, cell and gene therapy, and vaccines will drive HALIX’s future success and growth." Dr. Flore also acknowledged the contributions of Alex Huybens, saying, "We extend our gratitude to Alex for his outstanding leadership, which has set HALIX on a strong path forward."

HALIX’s Growing Influence in Biopharma

Founded on cutting-edge bioprocessing technologies, HALIX continues to focus on innovative solutions for developing biopharmaceuticals. The company utilizes scalable, single-use technologies in its GMP manufacturing process, allowing it to efficiently produce viral vectors and recombinant proteins at clinical and commercial scales. HALIX’s advanced facilities, including its 6,700 m² GMP manufacturing facility at Leiden Bio Science Park, house state-of-the-art equipment with 1,000 L SUB capacities.

In addition to its work with AstraZeneca, HALIX has secured contracts for producing oncolytic immunotherapies and vaccines, further solidifying its place in the biopharmaceutical industry. As part of the Droege Group, a family-owned investment company, HALIX benefits from strong financial backing, enabling it to pursue bold and innovative strategies in drug development and manufacturing.

With Dr. Hilbrich at the helm, HALIX is poised to continue its upward trajectory, driving the development of life-saving therapies for patients worldwide.